Equity Research for the following companies: Mistral Ventures (PINK:MILV), Lithium Exploration (OTC:LEXG), Salix (NASDAQ:SLXP), Portage Resources (PINK:POTG), Golden Star (AMEX:GSS) & Sirius (NASDAQ:SIRI).

MUMBAI, India, Oct. 5 /PRNewswire-FirstCall/ -- Pharma Major, Lupin Ltd today announced that it has granted Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) the exclusive rights for the United States to its bioadhesive drug delivery technology for use with Rifaximin.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the third quarter ended September 30, 2008. Total product revenue was $42.9 million for the third quarter of 2008, compared to $67.4 million for the third quarter of 2007.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO(TM) (mesalamine) extended-release capsules 0.375 g.

More Patients Switched to Mesalamine Granules Maintained Remission Versus Placebo (78 percent versus 59 percent) Salix Pharmaceuticals, Ltd. Adam C. Derbyshire Senior Vice President and Chief Financial Officer or G.